,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2019-02-17 07:00:00,The following are the top rated Healthcare stocks according to Validea's Value Investor model based on the published strategy of Benjamin Graham .,0.054452259093523026,0.004843269009143114,0.9407044649124146,neutral,0.0496089905500412
1,2019-02-17 07:00:00,"This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.",0.2132544368505478,0.012857495807111263,0.773888111114502,neutral,0.20039694011211395
2,2019-02-17 07:00:00,UNITED THERAPEUTICS CORPORATION ( UTHR ) is a mid-cap value stock in the Biotechnology & Drugs industry.,0.12496162950992584,0.006567221600562334,0.8684711456298828,neutral,0.1183944046497345
3,2019-02-17 07:00:00,The rating according to our strategy based on Benjamin Graham is 100% based on the firm's underlying fundamentals and the stock's valuation.,0.041064947843551636,0.004677549935877323,0.9542575478553772,neutral,0.03638739883899689
4,2019-02-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
5,2019-02-17 07:00:00,Company Description: United Therapeutics Corporation is a biotechnology company.,0.014488255605101585,0.008135340176522732,0.9773764610290527,neutral,0.006352915428578854
6,2019-02-17 07:00:00,The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions.,0.061649151146411896,0.0042084017768502235,0.9341424107551575,neutral,0.05744075030088425
7,2019-02-17 07:00:00,The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).,0.03540993854403496,0.00542250694707036,0.9591675400733948,neutral,0.029987432062625885
8,2019-02-17 07:00:00,"The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma.",0.08270557224750519,0.005279029253870249,0.9120153784751892,neutral,0.07742654532194138
9,2019-02-17 07:00:00,The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.,0.10041551291942596,0.0044503179378807545,0.8951341509819031,neutral,0.0959651917219162
10,2019-02-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
11,2019-02-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
12,2019-02-17 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

FUJIFILM HOLDINGS CORP. (ADR) ( FUJIY ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.38704150915145874,0.008102855645120144,0.6048556566238403,neutral,0.3789386451244354
13,2019-02-17 07:00:00,The rating according to our strategy based on Benjamin Graham is 86% based on the firm's underlying fundamentals and the stock's valuation.,0.037234753370285034,0.005011819303035736,0.9577534198760986,neutral,0.0322229340672493
14,2019-02-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
15,2019-02-17 07:00:00,"Company Description: FUJIFILM Holdings Corporation is engaged in the development, production, sales and service of imaging solutions, information solutions and document solutions.",0.020395169034600258,0.00616157753393054,0.9734432101249695,neutral,0.01423359103500843
16,2019-02-17 07:00:00,"The Company's segments include Imaging Solutions, Information Solutions, Document Solutions and, Corporate expenses and eliminations.",0.009510529227554798,0.01669258065521717,0.9737969040870667,neutral,-0.007182051427662373
17,2019-02-17 07:00:00,"The Imaging Solutions segment consists of photo imaging, and optical device and electronic imaging products.",0.01668498106300831,0.005735613405704498,0.9775794148445129,neutral,0.01094936765730381
18,2019-02-17 07:00:00,"The Information Solutions segment includes products used in medical systems, pharmaceuticals, regenerative medicine, life sciences, flat panel display (FPD) materials, industrial products, electronic materials, recording media and graphic systems.",0.016853181645274162,0.006016931496560574,0.9771298766136169,neutral,0.010836250148713589
19,2019-02-17 07:00:00,"The Document Solutions segment includes office products, office printers, production services and global services.",0.0174392219632864,0.005796982441097498,0.9767638444900513,neutral,0.01164223998785019
20,2019-02-17 07:00:00,"The Company's products include FUJI DRI-CHEM IMMUNO AG1, LASEREO, SYNAPSE Vendor Neutral Archive (VNA), FDR D-EVO II, SonoSite iViz, X FUJIFILM Index, FUJIFILM X-T2 and Instax Cameras Index.",0.022205760702490807,0.005815088748931885,0.9719792008399963,neutral,0.016390671953558922
21,2019-02-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
22,2019-02-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
23,2019-02-17 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BAXTER INTERNATIONAL INC ( BAX ) is a large-cap growth stock in the Medical Equipment & Supplies industry.",0.5010000467300415,0.009393168613314629,0.48960670828819275,positive,0.4916068911552429
24,2019-02-17 07:00:00,The rating according to our strategy based on Benjamin Graham is 71% based on the firm's underlying fundamentals and the stock's valuation.,0.031391967087984085,0.00518406555056572,0.963424026966095,neutral,0.026207901537418365
25,2019-02-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
26,2019-02-17 07:00:00,"Company Description: Baxter International Inc., through its subsidiaries, provides renal and hospital products.",0.016776859760284424,0.00666993809863925,0.9765532612800598,neutral,0.010106921195983887
27,2019-02-17 07:00:00,The Company operates through two segments: Hospital Products and Renal.,0.015520949847996235,0.00666307145729661,0.9778159856796265,neutral,0.008857877925038338
28,2019-02-17 07:00:00,"Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.",0.023244887590408325,0.005879237316548824,0.9708758592605591,neutral,0.017365649342536926
29,2019-02-17 07:00:00,"The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis ( HD ), continuous renal replacement therapy (CRRT) and additional dialysis services.",0.13980115950107574,0.004776298999786377,0.8554225564002991,neutral,0.13502486050128937
30,2019-02-17 07:00:00,"Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.",0.01395258679986,0.007541074883192778,0.9785063862800598,neutral,0.006411511916667223
31,2019-02-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
32,2019-02-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
33,2019-02-17 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

BAYER AG (ADR) ( BAYRY ) is a large-cap value stock in the Major Drugs industry.",0.1057300865650177,0.006175438407808542,0.888094425201416,neutral,0.0995546504855156
34,2019-02-17 07:00:00,The rating according to our strategy based on Benjamin Graham is 71% based on the firm's underlying fundamentals and the stock's valuation.,0.031391967087984085,0.00518406555056572,0.963424026966095,neutral,0.026207901537418365
35,2019-02-17 07:00:00,A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.,0.16861788928508759,0.00888283085078001,0.8224993348121643,neutral,0.1597350537776947
36,2019-02-17 07:00:00,Company Description: Bayer AG is a life science company.,0.01610603928565979,0.0062154745683074,0.9776785373687744,neutral,0.00989056471735239
37,2019-02-17 07:00:00,"The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health.",0.016119761392474174,0.005981110036373138,0.9778990745544434,neutral,0.010138651356101036
38,2019-02-17 07:00:00,"The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others.",0.02957594208419323,0.004577776417136192,0.9658463001251221,neutral,0.024998165667057037
39,2019-02-17 07:00:00,"The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others.",0.019435325637459755,0.0056155771017074585,0.974949061870575,neutral,0.013819748535752296
40,2019-02-17 07:00:00,"The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto.",0.018177557736635208,0.006221378222107887,0.9756010174751282,neutral,0.01195617951452732
41,2019-02-17 07:00:00,"The Animal Health segment is engaged in the development, production and marketing of prescription and nonprescription veterinary products.",0.016222093254327774,0.0057458421215415,0.9780319929122925,neutral,0.010476251132786274
42,2019-02-17 07:00:00,The following table summarizes whether the stock meets each of this strategy's tests.,0.05868730694055557,0.005839604884386063,0.9354730844497681,neutral,0.05284770205616951
43,2019-02-17 07:00:00,"Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.",0.023617705330252647,0.009007120504975319,0.9673751592636108,neutral,0.014610584825277328
44,2019-02-17 07:00:00,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here

Since its inception, Validea's strategy based on Benjamin Graham has returned 456.02% vs. 179.21% for the S&P 500.",0.6027580499649048,0.34759464859962463,0.04964735358953476,positive,0.25516340136528015
45,2019-02-17 07:00:00,"For more details on this strategy, click here

About Benjamin Graham : The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976.",0.06443396955728531,0.015505797229707241,0.9200602769851685,neutral,0.04892817139625549
46,2019-02-17 07:00:00,"Known as both the ""Father of Value Investing"" and the founder of the entire field of security analysis, Graham mentored several of history's greatest investors -- including Warren Buffett -- and inspired a slew of others, including John Templeton, Mario Gabelli, and another of Validea's gurus, John Neff.",0.27963581681251526,0.03247872367501259,0.6878854632377625,neutral,0.24715709686279297
47,2019-02-17 07:00:00,"Graham built his fortune and reputation after living through some extremely difficult times, including both the Great Depression and his own family's financial woes following his father's death when Benjamin was a young man.",0.3910258412361145,0.021684903651475906,0.5872892141342163,neutral,0.3693409264087677
48,2019-02-17 07:00:00,"His investment firm posted per annum returns of about 20 percent from 1936 to 1956, far outpacing the 12.2 percent average return for the market during that time.",0.795872151851654,0.018442975357174873,0.18568482995033264,positive,0.7774291634559631
49,2019-02-17 07:00:00,About Validea : Validea is an investment research service that follows the published strategies of investment legends.,0.01593991555273533,0.006665502674877644,0.9773945808410645,neutral,0.009274412877857685
50,2019-02-17 07:00:00,"Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",0.08751807361841202,0.010206559672951698,0.9022754430770874,neutral,0.07731151580810547
51,2019-02-17 07:00:00,"For more information about Validea, click here

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.009221813641488552,0.018771808594465256,0.9720064401626587,neutral,-0.009549994952976704
